Valuation: Immunovia AB

Market Cap 130M 13.64M 11.85M 10.89M 10.14M 19.23M 1.3B 19.51M 50.81M 635M 51.16M 50.06M 2.2B P/E 2026 *
-1.94x
P/E 2027 * -4.85x
Enterprise Value 63.5M 6.64M 5.77M 5.3M 4.94M 9.36M 631M 9.49M 24.72M 309M 24.89M 24.36M 1.07B EV / Sales 2026 *
19.8x
EV / Sales 2027 * 3.27x
Free-Float
89.3%
Yield 2026 *
-
Yield 2027 * -
1 day-32.03%
1 week+16,507.70%
Current month+16,370.59%
1 month+14,213.90%
3 months+17,042.86%
6 months+13,961.67%
Current year+13,658.62%
1 week 0.19
Extreme 0.1938
0.32
1 month 0.18
Extreme 0.1824
0.32
Current year 0.15
Extreme 0.1544
0.32
1 year 0.15
Extreme 0.1544
0.92
3 years 0.15
Extreme 0.1544
2.78
5 years 0.15
Extreme 0.1544
139.14
10 years 0.15
Extreme 0.1544
292
Manager TitleAgeSince
Chief Executive Officer 53 2023-04-28
Chief Tech/Sci/R&D Officer 55 2024-04-28
Chief Tech/Sci/R&D Officer 54 2024-01-30
Director TitleAgeSince
Director/Board Member 72 2016-12-08
Chairman 69 2023-05-25
Director/Board Member 51 2020-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-32.03%+16,507.70% - - 13.53M
-1.95%+1.16%+3.42%-29.47% 16.36B
+5.89%+23.51%+46.13%+98.40% 1.78B
+0.39%+32.34%-39.55%-78.08% 1.24B
+0.06%+3.85%-28.16%+33.46% 1.14B
+1.31%+4.95%-25.50%-53.22% 640M
+0.21%+3.42%-36.59%-57.01% 582M
-0.66%+3.11%+20.57%-55.49% 447M
+1.79%+0.16%-55.21%-60.69% 382M
+2.52%+7.65%-20.43%-19.03% 362M
Average -2.25%+7.61%-15.04%-24.57% 2.55B
Weighted average by Cap. -0.83%+4.51%+0.01%-21.27%

Financials

2026 *2027 *
Net sales 3.2M 334K 291K 267K 249K 472K 31.82M 478K 1.25M 15.56M 1.25M 1.23M 53.96M 17.3M 1.81M 1.57M 1.44M 1.34M 2.55M 172M 2.59M 6.74M 84.12M 6.78M 6.64M 292M
Net income -91M -9.51M -8.26M -7.59M -7.07M -13.41M -905M -13.6M -35.43M -442M -35.68M -34.91M -1.53B -82M -8.57M -7.45M -6.84M -6.37M -12.09M -815M -12.26M -31.93M -399M -32.15M -31.46M -1.38B
Net Debt -67M -7M -6.08M -5.59M -5.21M -9.87M -666M -10.01M -26.09M -326M -26.27M -25.7M -1.13B -74M -7.73M -6.72M -6.18M -5.75M -10.91M -736M -11.06M -28.81M -360M -29.01M -28.39M -1.25B
Logo Immunovia AB
Immunovia AB (publ) is a Sweden-based diagnostic company that is developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s test platform called IMMray. Tests are based on antibody biomarker microarray analysis using machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a disease biomarker signature. Immunovia Dx Laboratories locations in USA and Sweden provides laboratory testing services in two accredited reference laboratories.
Employees
17
Date Price Change Volume
26-06-29 SEK 0.1938 +0.83% 5

Quarterly revenue - Rate of surprise